Intra-tumoral injection of necroptotic cells promotes BATF3+ cDC1- and CD8+ leukocyte-dependent anti-tumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Here, CD8A is linked to neoplasm.